Spinogenix Targets Synaptic Regeneration with Small Molecule Drugs for Neurological Diseases
核心洞察
Spinogenix (搜索) is developing SPG302 and SPG601, orally administered small molecules, to restore synapses in neurological diseases like ALS (搜索), Alzheimer's, schizophrenia (搜索), and Fragile X syndrome (搜索).
SPG302, a Transient Activator of Glutamatergic Synaptogenesis (TAG), stimulates new synapse formation using glutamate (搜索) and is currently in Phase 2 trials across multiple indications.
Spinogenix (搜索) anticipates multiple Phase 2 readouts across disease areas in 2025, with potential for SPG302 as a standalone or cocktail therapy due to its safety profile.
Spinogenix (搜索), a Los Angeles-based company, is advancing two clinical candidates, SPG302 and SPG601, to address synaptic dysfunction in neurological diseases. These orally administered small molecules aim to restore synapses in diseases such as amyotrophic lateral sclerosis (搜索) (ALS (搜索)), Alzheimer’s disease (搜索), schizophrenia (搜索), and Fragile X syndrome (搜索). The company's approach focuses on synaptic regeneration, a novel target in neurodegenerative and neurodevelopmental conditions.
SPG302: A Novel Approach to Synaptic Regeneration
SPG302, discovered internally, is part of Spinogenix (搜索)’s TAG (Transient Activators of Glutamatergic Synaptogenesis) platform. This technology stimulates the formation of new synapses, utilizing glutamate (搜索) as a neurotransmitter. Currently, SPG302 is being evaluated in Phase 2 clinical trials for ALS (搜索), Alzheimer’s disease (搜索), and schizophrenia (搜索). These trials aim to optimize dosing and establish objective measurements of efficacy.
Stella Sarraf, Ph.D., founder of Spinogenix (搜索), highlighted the potential of targeting synaptic regeneration in ALS (搜索), stating, "The beauty of working at the synaptic level, especially in ALS, is that no one else has worked even in that zip code. It’s completely new."
SPG601: Targeting Synaptic Dysfunction in Fragile X Syndrome
SPG601, in-licensed from academia, is a small molecule BK channel (搜索) activator designed to correct synaptic dysfunction associated with Fragile X syndrome (搜索). This candidate is currently in a Phase 2 trial for Fragile X syndrome and has received orphan drug designation.
Biomarkers and Clinical Validation
Spinogenix (搜索) is leveraging technologies like electroencephalography (EEG) and transcranial magnetic stimulation (TMS) to objectively measure synapses and validate drug effectiveness. These tools serve as biomarkers, providing crucial data for clinical trials and regulatory submissions.
Strategic Collaborations and Funding
Spinogenix (搜索) has benefited from collaborations with academic institutions and grant funding from the NIH and Department of Defense. This support has enabled the company to de-risk its programs and conduct extensive animal studies. Sarraf noted, "All of our animal work was done by others [externally]," emphasizing the value of these collaborations.
Anticipated Milestones
Spinogenix (搜索) anticipates multiple Phase 2 readouts across disease areas in 2025. The company believes that SPG302’s safety profile could position it as a standalone therapy or as part of a combination therapy. The development of a safe and effective orally available treatment would be a significant advancement for patients with these debilitating conditions.
In October 2024, Spinogenix (搜索) launched an additional program in glaucoma (搜索) for SPG302, further expanding its pipeline and therapeutic potential.